$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000162828019013646 Filed on November 07, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$90.00K	$51.69K	$80.00K
YoY Change	12.5%	-41.5%	-56.76%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit	$90.00K	$51.69K	$80.00K
YoY Change	12.5%	-16.21%	-140.0%
Gross Profit Margin	100.0%	100.0%	100.0%
Selling, General & Admin	$1.520M	$1.440M	$1.680M
YoY Change	-9.52%	-13.5%	-9.19%
% of Gross Profit	1688.89%	2786.66%	2100.0%
Research & Development	$2.860M	$2.819M	$2.500M
YoY Change	14.4%	54.0%	103.25%
% of Gross Profit	3177.78%	5453.64%	3125.0%
Depreciation & Amortization	$360.0K	$40.00K	$160.0K
YoY Change	125.0%	-81.82%	-44.83%
% of Gross Profit	400.0%	77.39%	200.0%
Operating Expenses	$4.380M	$4.259M	$4.180M
YoY Change	4.78%	8.0%	5.32%
Operating Profit	-$4.290M	-$4.207M	-$4.100M
YoY Change	4.63%	9.13%	-1.66%
Interest Expense	$50.00K	$0.00	$110.0K
YoY Change	-54.55%	-100.0%	-92.03%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.103K	-$170.0K
YoY Change	-100.0%	-147.58%	0.0%
Pretax Income	-$4.240M	-$4.140M	-$4.160M
YoY Change	1.92%	9.81%	61.87%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$4.240M	-$4.142M	-$4.160M
YoY Change	1.92%	9.87%	61.87%
Net Earnings / Revenue	-4711.11%	-8012.75%	-5200.0%
Basic Earnings Per Share		-$0.71
Diluted Earnings Per Share	-$485.7K	-$0.71	-$1.081M
COMMON SHARES
Basic Shares Outstanding	7.742M shares	5.823M shares	22.99M shares
Diluted Shares Outstanding		5.823M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.20M	$9.000M	$11.50M
YoY Change	-11.3%	-40.4%	40.24%
Cash & Equivalents	$10.20M	$9.032M	$11.45M
Short-Term Investments
Other Short-Term Assets	$1.000M	$800.0K	$1.100M
YoY Change	-9.09%	0.0%	-8.33%
Inventory
Prepaid Expenses	$955.0K	$792.5K	$1.144M
Receivables	$203.5K	$152.0K	$167.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.35M	$9.977M	$12.77M
YoY Change	-11.06%	-37.81%	34.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$877.8K	$271.4K	$1.304M
YoY Change	-32.7%	-83.33%	-46.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$157.6K	$170.9K	$102.8K
YoY Change	53.29%	-31.53%	-73.64%
Total Long-Term Assets	$1.733M	$1.946M	$1.407M
YoY Change	23.14%	3.65%	-50.03%
TOTAL ASSETS
Total Short-Term Assets	$11.35M	$9.977M	$12.77M
Total Long-Term Assets	$1.733M	$1.946M	$1.407M
Total Assets	$13.09M	$11.92M	$14.17M
YoY Change	-7.66%	-33.47%	15.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$656.3K	$492.4K	$664.8K
YoY Change	-1.28%	3.37%	-19.44%
Accrued Expenses	$3.260M	$2.842M	$1.772M
YoY Change	83.99%	65.43%	21.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.782M	$4.171M	$2.923M
YoY Change	63.57%	56.41%	-25.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$128.4K	$1.100M	$42.00K
YoY Change	205.64%	-15.38%	-97.67%
Total Long-Term Liabilities	$128.4K	$1.100M	$42.00K
YoY Change	205.64%	-15.38%	-97.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.782M	$4.171M	$2.923M
Total Long-Term Liabilities	$128.4K	$1.100M	$42.00K
Total Liabilities	$5.775M	$5.266M	$4.088M
YoY Change	41.26%	33.63%	-29.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.9M	-$204.6M	-$192.2M
YoY Change	8.69%	8.84%	11.06%
Common Stock	$8.312K	$8.096K	$7.742K
YoY Change	7.36%	4.63%	46.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.312M	$6.656M	$10.08M
YoY Change
Total Liabilities & Shareholders Equity	$13.09M	$11.92M	$14.17M
YoY Change	-7.66%	-33.47%	15.36%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$4.240M	-$4.142M	-$4.160M
YoY Change	1.92%	9.87%	61.87%
Depreciation, Depletion And Amortization	$360.0K	$40.00K	$160.0K
YoY Change	125.0%	-81.82%	-44.83%
Cash From Operating Activities	-$3.280M	-$3.190M	-$3.610M
YoY Change	-9.14%	-8.33%	8.41%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$60.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$0.00	-$60.00K	$0.00
YoY Change		-200.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.440M	1.490M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-3.280M	-3.190M	-3.610M
Cash From Investing Activities	0.000	-60.00K	0.000
Cash From Financing Activities	4.440M	1.490M	0.000
Net Change In Cash	1.160M	-1.760M	-3.610M
YoY Change	-132.13%	-48.54%	-568.83%
FREE CASH FLOW
Cash From Operating Activities	-$3.280M	-$3.190M	-$3.610M
Capital Expenditures	$0.00	-$60.00K	$0.00
Free Cash Flow	-$3.280M	-$3.130M	-$3.610M
YoY Change	-9.14%	-10.06%	7.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	trov	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	76000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7742355	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	1371635	shares
	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	2592370	shares
CY2018	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y4M21D
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y2M0D
CY2018Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	8.91
CY2019Q3	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	7.00
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	4.15
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	2.81
	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	0	USD
	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	1675000	USD
CY2019Q1	trov	Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	40000	USD
CY2019Q1	trov	Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	235640	USD
	trov	Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	235640	USD
	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-576141	USD
	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	USD
	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-467009	USD
	trov	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2019Q3	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue	1409545	USD
CY2019Q3	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Five LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFive	3423	USD
CY2019Q3	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Four LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour	5868	USD
CY2019Q3	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree	676992	USD
CY2019Q3	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo	650497	USD
CY2019Q3	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear	72765	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
CY2019Q2	trov	Related Party Committed Expenditures RelatedPartyCommittedExpenditures	1070000	USD
	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	0	USD
CY2019Q1	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	-70487	USD
CY2019Q2	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	-240279	USD
CY2019Q3	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	-198268	USD
	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	509034	USD
	trov	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
	trov	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Net Of Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueNetOfSubleaseRentals	2500542	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Net Of Sublease Rentals Next Twelve Months OperatingLeasesFutureMinimumPaymentsDueNetOfSubleaseRentalsNextTwelveMonths	581416	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Five Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInFiveYears	3423	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Four Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInFourYears	5868	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Three Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInThreeYears	968165	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Two Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInTwoYears	941670	USD
CY2018Q2	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-11779525	USD
CY2019Q2	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-2902740	USD
CY2019Q3	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-1483581	USD
CY2018Q4	trov	Servicereceivable Servicereceivable	0	USD
CY2019Q3	trov	Servicereceivable Servicereceivable	1165966	USD
CY2019Q1	trov	Servicereceivable Servicereceivable	1675000	USD
CY2018Q1	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1449167	USD
CY2018Q2	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	163500	USD
CY2019Q1	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3282266	USD
CY2019Q2	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1564	USD
CY2019Q3	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7180	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	664840	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	492367	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	167755	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	152038	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1813842	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2842153	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2110061	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1350715	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202267605	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212463077	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1406131	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	221300	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	278221	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	200067	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	148834	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	266325	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	278221	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1905652	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	266324	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	615226	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3818320	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5901540	shares
CY2018Q4	us-gaap	Assets Assets	14172496	USD
CY2019Q3	us-gaap	Assets Assets	11922463	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	12765265	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	9976784	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11453133	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9032206	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8225764	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15065913	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11453133	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9032206	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6840149	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2420927	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3649341	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4870076	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3831880	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6436505	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3831880	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6436505	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	7742	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	8096	USD
CY2019Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	333333	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	333333	shares
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	26677	USD
	us-gaap	Cost Of Revenue CostOfRevenue	597457	USD
CY2019Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	486636	USD
CY2019Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1090671	USD
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	701774	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	130219	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	32315	USD
CY2019Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4956	USD
CY2018Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2018Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2018Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2019Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2019Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2019Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.27
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.46
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.27
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.46
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-197490	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	17974	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	383037	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	837551	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-58440	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15717	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	266556	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	170602	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	68145	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-316746	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-277876	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	16	USD
	us-gaap	Interest Expense InterestExpense	25177	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2018Q3	us-gaap	Interest Income Operating InterestIncomeOperating	85938	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	143911	USD
CY2019Q3	us-gaap	Interest Income Operating InterestIncomeOperating	53700	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	188204	USD
	us-gaap	Interest Paid Net InterestPaidNet	22482	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	91535	USD
	us-gaap	Lease Cost LeaseCost	279107	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2073732	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3423	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5868	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	968165	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	941670	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	154606	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	146725	USD
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	664187	USD
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	0	USD
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22842	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67622	USD
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	81841	USD
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	291173	USD
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	291173	USD
CY2018Q4	us-gaap	Liabilities Liabilities	4088304	USD
CY2019Q3	us-gaap	Liabilities Liabilities	5266483	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14172496	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11922463	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2965318	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4170814	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16403540	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7637331	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9586233	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9990636	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-4786177	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-3746955	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-3769568	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12302700	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3904771	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-4125303	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4141549	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12171623	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3775628	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15090413	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4147609	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12458072	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3775628	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15090413	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4147609	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12458072	USD
CY2018Q1	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	109922	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	3943669	USD
	us-gaap	Operating Expenses OperatingExpenses	13250237	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	4259163	USD
	us-gaap	Operating Expenses OperatingExpenses	12541253	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3855308	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12949927	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4207476	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12389198	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	191472	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	578919	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1927007	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2503000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5868	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	836294	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1090713	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	229927	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	685865	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1503335	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1970000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M4D
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2833666	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	914540	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3423	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	968165	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	941670	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	333124	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	333124	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	0	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	102798	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170943	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2318	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68521	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1103	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2012	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	175381	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	31500	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5100	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67622	USD
CY2018Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2019Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1144377	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	792540	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11779525	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1200033	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4386321	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4400000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	4386762	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-40000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	31500	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	27942	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1612667	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3300000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3291010	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3414494	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1622116	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1304433	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	271401	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1830441	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5667046	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2818824	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8297763	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	421351	USD
	us-gaap	Restructuring Charges RestructuringCharges	664686	USD
CY2019Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	187500	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192191215	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-204649287	USD
CY2018Q3	us-gaap	Revenues Revenues	88361	USD
	us-gaap	Revenues Revenues	300310	USD
CY2019Q3	us-gaap	Revenues Revenues	51687	USD
	us-gaap	Revenues Revenues	152055	USD
CY2019Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2503148	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1665200	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6321048	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1440339	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4243490	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1905652	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	615226	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1515946	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	321870	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4386762	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-40000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6506107	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	4679090	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	17477162	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	13979755	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10084192	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	9686181	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	8848235	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	6655980	USD
CY2019Q3	us-gaap	Sublease Income SubleaseIncome	99937	USD
	us-gaap	Sublease Income SubleaseIncome	299812	USD
CY2018Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2500	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	579040	USD
CY2019Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	13330	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	27359	USD
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3437100	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1824208	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5822818	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5056794	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3437100	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1824208	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5822818	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5056794	shares

Files In Submission

Name	View Source	Status
0001628280-19-013646-index-headers.html	Edgar Link	pending
0001628280-19-013646-index.html	Edgar Link	pending
0001628280-19-013646.txt	Edgar Link	pending
0001628280-19-013646-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-093019exhibit311.htm	Edgar Link	pending
trov-093019exhibit312.htm	Edgar Link	pending
trov-093019exhibit321.htm	Edgar Link	pending
trov-093019exhibit322.htm	Edgar Link	pending
trov-093019x10q.htm	Edgar Link	pending
trov-20190930.xml	Edgar Link	completed
trov-20190930.xsd	Edgar Link	pending
trov-20190930_cal.xml	Edgar Link	unprocessable
trov-20190930_def.xml	Edgar Link	unprocessable
trov-20190930_lab.xml	Edgar Link	unprocessable
trov-20190930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2019 Q4 Form 10-Q Financial Statement

#000162828019013646 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2019 Q4 Form 10-Q Financial Statement

#000162828019013646 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf